ACTRN12612000140853已完成2 期
Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation into tumour Gene status and Correlation with Efficacy – 1st exploratory study
Auckland District Health Board (ADHB)0 个研究点目标入组 30 人开始时间: 2012年2月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Advanced / metastatic renal cell (clear cell) carcinoma
- •FFPE tumour tissue available for gene status analysis
- •ECOG PS = 1
- •Adequate organ function
排除标准
- •Uncontrolled brain metastases
- •Another primary malignancy < 3 years prior to starting study treatment
- •Prior systemic anticancer treatment
- •Uncontrolled hypertension
- •Impaired cardiac function; clinically significant cardiac disease
- •Concurrent severe and/or uncontrolled concomitant medical conditions
研究者
相似试验
Unknown
2 期
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCCClear Cell Renal Cell CarcinomaNCT01791387Auckland District Health Board30
招募中
3 期
A clinical trial to study the effects Adjuvant Axitinib in patients at High Risk of Recurrent Renal Cell CarcinomaCTRI/2012/09/002999SFJ Pharma Ltd II592
进行中（未招募）
1 期
A study of axitinib compared to placebo in the treatment of patients with renal cell carcinoma (kidney cancer)Renal Cell CarcinomaEUCTR2013-003905-24-ESSFJ Pharma Ltd. II592
招募中
不适用
A phase II trial of dovitinib monotherapy as salvage treatment in patients with metastatic or unresectable gastric cancer harboring FGFR2 amplification after failureDiseases of the digestive systemKCT0001256Asan Medical Center31
进行中（未招募）
1 期
PHASE II CLINICAL TRIAL OF DOVITINIB (TKI-258) IN FIRST-LINE METASTATIC OR LOCALLY ADVANCED NON-RESECTABLE ADRENOCORTICAL CARCINOMAEUCTR2011-002873-47-ESGrupo Español de Oncología Genitourinaria (SOGUG)